Table 4 Potential factors associated with treatment-free remission
Parameter | Patients | Estimated SWMR at 12 months, % (95% CI) | p value |
|---|---|---|---|
Age, years | 0.965 | ||
> 64 | 12 | 16.6 (9.1–24.0) | |
≤ 64 | 13 | 47.0 (21.8–72.2) | |
Sex | 0.325 | ||
Male | 10 | 59.6 (31.2–88.0) | |
Female | 15 | 20.3 (9.6–30.9) | |
Sokal risk score | 0.707 | ||
Low | 10 | 59.5 (31.0–88.0) | |
Intermediate | 10 | 13.4 (6.5–20.3) | |
High | 5 | 9.4 (5.5–13.3) | |
Transcript type | 0.393 | ||
e14a2 | 14 | 51.5 (27.7–75.3) | |
e13a2 | 7 | 15.3 (5.2–25.4) | |
e14a2 + e13a2 | 4 | 8.3 (1.0–15.5) | |
TKI therapy, months | 0.026 | ||
> 60 | 20 | 55.4 (35.2–75.6) | |
≤ 60 | 5 | 5.4 (3.6–7.2) | |
TKI therapy, months | 0.040 | ||
> 96 | 16 | 62.0 (39.9–84.1) | |
≤ 96 | 9 | 10.7 (1.5–19.8) | |
Molecular Response | 0.016 | ||
SDMR | 19 | 53.7 (33.1–74.2) | |
UDMR | 6 | 6.3 (1.3–11.4) | |
Molecular Response + TKI therapy, months | 0.003 | ||
SDMR + > 60 | 16 | 62.7 (41.0–84.4) | |
UDMR + ≤60 | 9 | 6.1 (2.7–9.6) | |
Molecular Response + TKI therapy, months | 0.003 | ||
SDMR + > 96 | 12 | 73.9 (51.3–96.5) | |
UDMR + ≤96 | 13 | 11.9 (2.9–20.8) |